Table 1.
Comparison of patient demographics between different treatment groups
| Group 1, Aggressive treatment (N = 59) |
Group2, Supportive treatment (N = 23) |
P value | |
|---|---|---|---|
| Age at biopsy | 50.5 [42.7–58.8] | 55.6 [47.1–65.3] | 0.052 |
| Donor type | 0.245 | ||
| Deceased | 43 (74.1%) | 19 (86.4%) | |
| Living | 15 (25.9%) | 3 (13.6%) | |
| Transplant duration (mo) | 95.6 [62.2–161.6] | 123.2 [68.9–209.4] | 0.394 |
| Follow up duration (mo) | 34.7 [27.7–50.9] | 30.9 [14.8–44.8] | 0.163 |
| DM | 9 (16.7%) | 3 (13.0%) | 0.690 |
| HBV | 5 (9.1%) | 1 (4.3%) | 0.476 |
| HCV | 8 (14.5%) | 4 (17.4%) | 0.752 |
| HLA mismatches | 2.0 [0.0–3.5] | 0.0 [0.0–1.0] | 0.279 |
| PRA | |||
| Class I | 0.0 [0.0–15.6] | 0.0 [0.0–0.0] | 0.293 |
| Class II | 19.0 [0.0–58.5] | 32.0 [0.0–81.7] | 0.911 |
| Induction | 0.657 | ||
| ATG | 1 (1.8%) | 0 (0.0%) | 0.388 |
| Anti-CD 25 | 12 (28.6%) | 3 (13.0%) | |
| No induction | 30 (71.4%) | 20 (87.0%) | |
| Regimen | 0.498 | ||
| CsA based | 16 (30.2%) | 7 (38.9%) | |
| FK-506 based | 37 (69.8%) | 11 (61.1%) | |
| Drug level | |||
| CsA (ng/ml) | 101.0 [89.1–121.0] | 122.0 [91.1–132.0] | 0.697 |
| FK-506 (ng/ml) | 5.3 [4.2–6.2] | 5.3 [3.7–6.8] | 0.663 |
| Creatinine (mg/dL) | 1.8 [1.4–2.4] | 1.84 [1.5–2.9] | 0.635 |
| eGFR (ml/min/1.73m2) | 31.3 [23.3–45.8] | 24.7[19.9–40.3] | 0.148 |
| Proteinuria (g/d) | 0.5 [0.2–1.7] | 1.5 [0.4–2.0] | 0.094 |
| Banff score | |||
| cg | 1.0 [0.0–2.0] | 1.5 [1.0–3.0] | 0.052 |
| ci + ct | 2.0 [2.0–2.0] | 2.0 [2.0–2.5] | 0.136 |
| mm | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 0.959 |
| g + ptc | 3.5 [2.0–4.0] | 3.0 [2.0–3.0] | 0.158 |
cg transplant glomerulopathy, ci interstitial fibrosis, ct tubular atrophy, mm mesangial matrix increase, g glomerulitis, ptc peritubular capillary inflammation